Stryker reported strong Q3 2025 top-line growth with Net Sales of $6,057M (+10.3% YoY), leading to Net Earnings of $859M (+3.0% YoY). However, 9-month Year-to-Date (YTD) performance showed margin pressure, with Net Earnings declining 2.0% to $2,397M and Diluted EPS falling 2.4% to $6.20. Operating Margin contracted to 18.7% due to increased SG&A and significant asset impairments ($73M in Q3; $163M YTD).
Strategic activity was dominated by major M&A integration and divestiture. The Inari acquisition ($4.81B) fueled robust growth in the MedSurg and Neurotechnology segment (sales +14.
...